TIM-4 increases the proportion of CD4 + CD25 + FOXP3 + regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL-6 secretion.
Ziyao WangZerong XieYu MouRuiman GengChen ChenNeng-Wen KePublished in: Cancer medicine (2024)
TIM-4 has the potential to be an immunotherapeutic target or to improve the efficacy of chemotherapy for PDAC.